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Abstract
Granzyme-mediated cell death is the major pathway for cytotoxic lymphocytes to kill virus-infected and tumor cells. In
humans, five different granzymes (i.e. GrA, GrB, GrH, GrK, and GrM) are known that all induce cell death. Expression of
intracellular serine protease inhibitors (serpins) is one of the mechanisms by which tumor cells evade cytotoxic lymphocyte-
mediated killing. Intracellular expression of SERPINB9 by tumor cells renders them resistant to GrB-induced apoptosis. In
contrast to GrB, however, no physiological intracellular inhibitors are known for the other four human granzymes. In the
present study, we show that SERPINB4 formed a typical serpin-protease SDS-stable complex with both recombinant and
native human GrM. Mutation of the P2-P1-P19 triplet in the SERPINB4 reactive center loop completely abolished complex
formation with GrM and N-terminal sequencing revealed that GrM cleaves SERPINB4 after P1-Leu. SERPINB4 inhibited GrM
activity with a stoichiometry of inhibition of 1.6 and an apparent second order rate constant of 1.36104 M21s21. SERPINB4
abolished cleavage of the macromolecular GrM substrates a-tubulin and nucleophosmin. Overexpression of SERPINB4 in
tumor cells inhibited recombinant GrM-induced as well as NK cell-mediated cell death and this inhibition depended on the
reactive center loop of the serpin. As SERPINB4 is highly expressed by squamous cell carcinomas, our results may represent
a novel mechanism by which these tumor cells evade cytotoxic lymphocyte-induced GrM-mediated cell death.
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Introduction
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells
(i.e. cytotoxic lymphocytes) play a pivotal role in the effector arm of
the immune response that eliminate virus-infected cells and tumor
cells [1]. Cytotoxic lymphocytes predominantly destroy their
target cells by releasing the content of their cytolytic granules.
These granules contain perforin and a family of unique
structurally homologous serine proteases known as granzymes
[2]. While perforin facilitates the entry of granzymes into the
target cell, the latter induce cell death by cleaving critical
intracellular substrates [3].
In humans, five different granzymes (GrA, GrB, GrH, GrK,
and GrM) are known that differ on the basis of their substrate
specificity [4]. All granzymes induce cell death with partially
overlapping morphological hallmarks [4]. While GrA and GrB
have been extensively studied, far less is known about the
molecular cell death mechanisms of the other human granzymes
[5]. Recently, it has been demonstrated that GrM, which is highly
expressed by NK cells, NKT cells, cd-T cells, and CD8+ effector T
cells [6,7,8], mediates a major and novel perforin-dependent cell
death pathway that plays a significant role in cytotoxic lymphocyte
induced death [9]. In tumor cell lines, GrM directly and efficiently
cleaves a diverse set of substrates, i.e. ICAD, PARP, HSP75, ezrin,
a-tubulin, PAK 2, survivin, and nucleophosmin [10,11,12,13,14].
Tumor cells can escape from cytotoxic lymphocyte-induced
killing by expression of cell death inhibitors in their cytoplasm, like
the caspase-inhibitors XIAP and FLIP [15,16], and the GrB-
inhibitor SERPINB9 (PI9) [17]. SERPINB9 is the only known
intracellular human granzyme inhibitor and protects against GrB-
induced apoptosis [17,18]. Expression of SERPINB9 is associated
with a poor clinical outcome in various types of tumors (e.g.
lymphomas and melanomas) [19,20,21]. SERPINB9 belongs to
the intracellular (B-clade) sub-family of human serine protease
inhibitors (serpins). Serpins share a unique inhibitory mechanism.
Upon cleavage by a specific target protease in their reactive center
loop (RCL), serpins undergo a conformational change after which
the serpin and the target protease are covalently bound, leaving
the latter kinetically inactive [22].
In contrast to GrB, no physiological intracellular inhibitors are
known for the other four human granzymes [23]. Since GrM is a
very potent specialized inducer of tumor cell death [5,24] and
plays an important role in anti-tumor function in vivo [25], we
aimed to identify an intracellular inhibitor of human GrM. In the
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present study, we demonstrate that SERPINB4 [also called
squamous cell carcinoma antigen 2 (SCCA-2) or leupin] directly
inhibits human GrM proteolytic activity and that overexpression
of SERPINB4 in HeLa cells inhibits recombinant GrM-induced as
well as NK cell-mediated cell death. This may represents a novel
mechanism by which tumor cells evade GrM-mediated killing by
cytotoxic lymphocytes.
Materials and Methods
Recombinant proteins
Expression and purification of recombinant human GrM and
the catalytically inactive GrM-SA variant was performed as
described previously [10]. Briefly, cDNA encoding mature human
GrM (residues Ile26-Ala257) was cloned into the yeast expression
vector pPIC9 (Invitrogen, Paisley, UK). Catalytically inactive
GrM-SA, in which the Ser195 residue in the catalytic center is
replaced by Ala, was generated by site-directed mutagenesis
(Stratagene, Cedar Creek, TX). Plasmids were transformed into
the GS115 strain of P. pastoris (Invitrogen) and granzymes were
expressed in conditioned media for 72 h. Recombinant GrM and
GrM-SA were purified to homogeneity by cation-exchange
chromatography (GE Healthcare, Diegem, Belgium) and dialyzed
against 50 mM Tris (pH 7.4) and 150 mM NaCl. Recombinant
GrM, but not GrM-SA, was active as determined by a synthetic
chromogenic leucine substrate (Bachem, Weil am Rhein, Ger-
many).
Expression and purification of recombinant SERPINB4 wild
type and SERPINB4 RCL-mutant was performed using the
expression vector pRSETC (Invitrogen) as described previously
[26]. SERPINB4, coding an N-terminal His6-tagged fusion
protein, and SERPINB4 RCL-mutant, in which the P2-Glu353,
P1-Leu354, P19-Ser355 amino acids were mutated into P2-Gln353,
P1-Gly354, P19-Ala355, were expressed in E.coli BL21 (DE3) using
Overnight Express auto inducing medium (Merck, Nottingham,
UK) containing 100 mg/ml ampicillin. Following growth at 37uC
for 24 h, cells were harvested by centrifugation at 15,000 g for
30 minutes and lysed using Bugbuster (Merck) lysis reagent.
Soluble material was clarified by centrifugation of the lysate at
21,000 g for 30 minutes at 4uC. The recombinant serpin was
purified using a His-Bind Purification kit (Merck). Pooled
imidazole eluted fractions were buffer exchanged into 50 mM
Tris pH 8.0 and recombinant protein was stored at 280uC until
required. Concentrations of the purified proteins were measured
according to the procedure of Bradford (Bio-Rad, Hercules, CA).
Generation of a novel mAb against human GrM
Mice were immunized with purified recombinant human GrM.
Obtained hybridomas were screened for antibodies that reacted
with GrM in different applications as previously described [27].
Anti-GrM mAb 3D4D7 (IgG1 isotype) was highly sensitive against
Western-blotted recombinant GrM as well as native GrM from
NK cell lysates (Fig. 1). Cross-reactivity of mAb 3D4D7 against
recombinant human GrB and GrK was excluded (data not
shown).
Cell culture and transfection
293T and Jurkat cells were maintained in DMEM and RPMI-
1640 medium (Invitrogen), respectively, supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (Sigma), 100 U/ml
penicillin, and 100 mg/ml streptomycin (Invitrogen). The human
NK cell line KHYG-1 [28] was purchased from the Health
Science Research Resources Bank (JCRB0156) of the Japan
Health Sciences Foundation and cultured similarly to Jurkat cells,
with the addition of 50 ng/ml recombinant human interleukin 2
(Wako, Osaka, Japan). The previously described HeLa cell lines,
stably transfected with pcDNA3 SERPINB4, pcDNA3 SER-
PINB4 RCL-mutant, or pcDNA3 vector only [26], were cultured
similarly to 293T cells, with the addition of G418 (0.5 mg/ml).
The plasmid pEGFP-N1 containing C-terminal green fluorescent
protein (GFP)-tagged SERPINB4 (kindly provided by Dr. Wun-
Shaing W. Chang, National Institute of Cancer Research,
National Health Research Institutes, Taiwan, ROC) or mock
control vector were transiently transfected into 293T cells using
linear polyethylenimine (PEI) (Polysciences, Warrington, PA),
according to the manufacturer’s instructions. Cell lysates were
prepared by three freezing-thawing cycles in liquid nitrogen of
cells resuspended in a buffer containing 20 mM Tris (pH 7.4) and
150 mM NaCl. Protein concentrations of the supernatants were
measured according to the procedure of Bradford.
Analysis of complex formation by SDS-PAGE and
immunoblotting
Indicated amounts of purified recombinant SERPINB4 and
GrM proteins were incubated in 20 mM Tris (pH 7.4) and
150 mM NaCl for 1 h at 37uC. When noted, Jurkat or KHYG-1
cell lysate was incubated with the recombinant protein(s) for the
indicated times at 37uC. Samples containing recombinant proteins
only were additionally treated with PNGase F (New England
Figure 1. SERPINB4 forms a typical serpin-protease SDS-stable
complex with recombinant and native human GrM. (A) Purified
recombinant GrM (1.8 mM) and SERPINB4 (1.8 mM) were incubated for
1 h at 37uC. All samples were treated with PNGase F, separated by SDS-
PAGE, and analyzed by SimplyBlue staining. (B) Cell lysate of the NK cell
line KHYG-1 (33 mg) was incubated with recombinant SERPINB4 (0, 50,
150, and 450 ng) for 2 h at 37uC. Subsequently, samples were
immunoblotted for native GrM. GrM, SERPINB4, GrM-SERPINB4 com-
plexes, and cleaved SERPINB4 (SERPINB4*) are indicated.
doi:10.1371/journal.pone.0022645.g001
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BioLabs, Ipswich, MA), according to the manufacturer’s instruc-
tions. Subsequently, samples were separated on 10% SDS-PAGE
gels under reducing conditions. For SDS-PAGE analysis, gels were
stained with SimplyBlue (Invitrogen), according to the manufac-
turer’s instructions. For immunoblot analysis, proteins were
transferred onto immobilon–P membranes (Millipore, Billerica,
MA). After blocking with 5% (w/v) Marvel dried skimmed milk
(Premier International Foods, Coolock, UK) in TBS-T (10 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20), membranes
were incubated for two hours at RT with our novel mouse anti-
human GrM mAb (clone 3D4D7; 1.0 mg/ml), mouse anti-human
a-tubulin mAb (clone B-5-1-2; 0.4 mg/ml) (Sigma), mouse anti-
human nucleophosmin (clone FC-61991; 2.0 mg/ml) (Invitrogen),
rabbit anti-human nm23H-1 (clone C-20:sc-343; 1.0 mg/ml)
(Santa Cruz Biotechnology, Santa Cruz, CA), or mouse anti-
human b-actin mAb (clone 2A2.1) (US Biological, Swampscott,
MA). Goat anti-mouse IgG+IgM HRP (Biosource, Camarillo, CA)
conjugate was used as secondary antibody. Bound antibodies were
visualized using 3,39-diaminobenzidine (DAB) (0.6 mg/ml) or
enhanced chemiluminescence substrate (ECL) (GE Healthcare).
Immunoprecipitation
Cell lysates of mock and GFP-tagged SERPINB4 transfected
293T cells were incubated with 10 mg/ml anti-GFP mAb (Roche,
Mannheim, Germany) and protein A/G plus-agarose (Santa Cruz
Biotechnology), and rotated end-over-end in non-sticky microfuge
tubes (Ambion, Austin, TX) for 16 h at 4uC. Precipitates were
washed three times with 50 mM Tris (pH 7.4), 150 mM NaCl and
incubated with 2.3 mM rh-GrM for 1 h at 37uC. Next, the samples
were washed twice more and finally boiled in reducing Laemmli
sample buffer. Immunoblotted samples were stained by Coomassie
Brilliant Blue (BioRad) and the cleavage-product of interest was
excised and identified by Edman degradation, using a 476A
protein sequencer (Applied Biosystems, Foster City, CA).
Stoichiometry of inhibition
Increasing concentrations (0–3 mM) of recombinant SERPINB4
was incubated with a constant amount of recombinant human
GrM (2 mM) in 50 mM Tris (pH 7.4) and 150 mM NaCl for 2 h
at 37uC. Samples were diluted 10-fold in 100 mM Tris (pH 7.4),
200 mM NaCl, and 0.01% Tween containing 1 mM synthetic
chromogenic leucine substrate (AAPL-pNA) (Bachem) to termi-
nate the inhibition reactions and transferred to a microplate
(Greiner, Kremsmunster, Austria) to assay residual GrM activity.
The velocity of substrate hydrolysis by residual active GrM was
measured at A405 using a microtiter plate reader (Anthos,
Cambridge, UK). The fractional activity (velocity of GrM with a
serpin/velocity of GrM only) was plotted against the ratio of
[serpin]0/[GrM]0. Linear regression analysis was used to deter-
mine the x-axis intercept as a value for the stoichiometry of
inhibition.
Apparent second order rate constant
The interaction of SERPINB4 with GrM was determined under
second order conditions [29]. Recombinant GrM was incubated
with recombinant SERPINB4 at equimolar concentrations.
Samples of this reaction were taken after 30, 60, 120, 180, 240
and 360 seconds and directly diluted 20-fold in 100 mM Tris
(pH 7.4), 200 mM NaCl, and 0.01% Tween containing 1 mM of
the chromogenic substrate AAPL-pNA. The rate of substrate
hydrolysis by GrM was measured in time at A405 using a microtiter
plate reader (Anthos). Since serpin-serine protease interactions are
irreversible, velocities of the substrate hydrolysis were converted to
residual active GrM concentrations using a GrM concentration
standard curve incubated without SERPINB4. The rate of change
in the amount of residual active GrM over time is described in
equation (1), where the slope of the plot of reciprocal residual
active GrM over time yields the apparent second order rate
constant (kinh).
1= residual active GrM½ ~kinh|tz1

GrM½ 0 ð1Þ
RT-PCR and immunoblot analysis for SERPINB4
expression
RNA was isolated from (stably transfected) HeLa cells using RNA
isolatorTM (Genosys). RNA (1–5 mg) was reverse transcribed using
MMLV-reverse transcriptase, and the resulting cDNA was used for
RT-PCR amplification. The following primers were used: GAPDH-
sense 59-TGAAGGTCGGAGTCAACG-39, GAPDH-antisense 59-
CATGTGGGCCATGAGGTC-39, SERPINB4-sense 59-GGGGG-
ATCCATATGAATTCACTCAGTGAAG-39, and SERPINB4-an-
tisense 59-CCCCCGGGTACCTACGGGGATGAGAATCTG-39.
Immunoblot analysis for SERPINB4 protein expression by (stably
transfected) HeLa cells was performed as previously described [26].
Granzyme M killing assays
HeLa cells stably transfected with SERPINB4 or SERPINB4
RCL-mutant were grown to confluence in a 96-well tissue-culture
plate. Cells were washed twice in serum-free DMEM, after which
they were incubated at 37uC with a sublytic dose of streptolysin O
(SLO) (0.5 mg/ml) (Sigma) and indicated concentrations of
granzyme in serum-free DMEM for 30 min. Cells were washed
twice with supplemented DMEM, after which cells were incubated
for indicated periods of time at 37uC. For the methylene blue
assay, cells were carefully washed with PBS and remaining
adherent cells were fixed with methanol for 30 min at room
temperature. After drying, cells were stained with 0.05% (w/v)
methylene blue dye (Merck) in borate-buffered saline (pH 8.4) for
15 min, washed 3 times with water, and air dried. Bound dye was
dissolved in 0.1 N HCl (100 ml/well) and measured photospec-
trometrically at 630 nm. To assess cell viability by flow cytometry,
cells were stained with AnnexinV-fluos (Invitrogen) and propidium
iodide (PI) for 15 min in a buffer containing 140 mM NaCl,
4 mM KCl, 0.75 mM MgCl2, 1.5 mM CaCl2, and 10 mM
HEPES (pH 7.4). Flow cytometry was performed on a FACSCa-
libur (BD Biosciences) and data was analyzed using CellQuest Pro
software (BD Biosciences).
NK-cell mediated cytotoxicity assay
HeLa cells stably transfected with SERPINB4 or SERPINB4
RCL-mutant were grown to confluence in a 96-well tissue-culture
plate and loaded for 10 min with 10 mM of the fluorescent cell
staining dye carboxyfluorescein diacetate succinimidyl ester
(CFDA-SE). These HeLa cells were co-cultured with KHYG-1
NK cells in varying E:T ratio’s for 16 h at 37uC. Cells were stained
with PI and analyzed by flow cytometry. During data analysis, a
gate on CFDA-SE positive cells was used to distinguish between
KHYG-1 and HeLa cells. The percentage of living untreated
HeLa cells was set at 100% and the percentages of treated cells
were matched correspondingly, after which the percentage of
specific cytotoxicity was calculated.
Statistical analysis
All statistical analyses were performed using the Student’s t-test.
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Results
SERPINB4 forms a typical serpin-protease SDS-stable
complex with human GrM
Upon cleavage by a specific target protease, most serpins form
SDS-stable covalent-bound complexes with that protease, in which
the latter one becomes inactive [22]. Since human GrM displays a
restricted cleavage site specificity in that it predominantly cleaves
after P1-Leu [10,11,12,30] and that SERPINB4 is the only human
intracellular B-clade serpin that harbours a Leu at the putative P1-
position in its RCL [31,32], we investigated complex formation of
SERPINB4 with GrM by SDS-PAGE analysis using purified
recombinant proteins (Fig. 1A). Purified recombinant GrM and
SERPINB4 migrated with a molecular mass of 28 and 44 kDa,
respectively (Fig. 1A, left and right lane). Incubation of GrM with
SERPINB4 revealed an SDS-stable complex band with the
expected molecular mass of around 70 kDa (Fig. 1A, middle
lane). The majority of SERPINB4 molecules formed a complex
with GrM, whereas a small fraction of SERPINB4 was cleaved by
GrM without trapping this protease. Next, we studied whether
SERPINB4 could also bind to and form an SDS-stable complex
with native human GrM (Fig. 1B). The human NK cell line
KHYG-1 was used as a source for native GrM. Incubation of a
KHYG-1 cell lysate with recombinant SERPINB4 and subsequent
immunoblotting for the protease revealed the formation of a
complex between native GrM and recombinant SERPINB4 in a
concentration-dependent manner (Fig. 1B). These data demon-
strate that SERPINB4 forms a classical SDS-stable serpin-protease
complex with both recombinant and native human GrM.
GrM cleaves SERPINB4 in its RCL after P1-Leu
To investigate if complex formation of SERPINB4 with GrM
depends on the RCL and corresponding conformational change of
the serpin, a RCL-mutant of SERPINB4 was employed in which
the amino acids at the putative P2(Glu353)-P1(Leu354)-P19(Ser355)
positions were mutated into P2(Gln353)-P1(Gly354)-P19(Ala355).
Western blot analysis for GrM revealed a complex with a
molecular mass of about 70 kDa when the purified recombinant
wild type proteins of GrM and SERPINB4 were incubated
(Fig. 2A). In contrast, no complex formation was detected upon
incubation of SERPINB4 RCL-mutant with GrM. Furthermore, a
mutated catalytically inactive counterpart of GrM was included
(GrM-SA). As expected, this GrM-SA was not able to form a
complex with SERPINB4 (Fig. 2A). Thus, complex formation of
SERPINB4 with GrM appears to depend on the RCL of the
serpin and the catalytic triad of the protease.
Next, the cleavage site of GrM in the RCL of SERPINB4 was
determined. Therefore, cell lysates of 293T cells expressing either
C-terminal GFP-tagged full length SERPINB4 or an empty vector
were incubated with GrM. Immunoblotting for GFP showed a C-
terminal cleavage product of SERPINB4 (SERPINB4*-GFP) with
the expected molecular mass of about 29 kDa (Fig. 2B), as the
RCL of SERPINB4 is near its C-terminus and the molecular mass
of the linked GFP is about 25 kDa. Immunoprecipitation of GFP-
conjugated SERPINB4 from 293T cell lysate and N-terminal
sequencing of the subsequent GrM-induced C-terminal cleavage
fragment revealed that GrM indeed cleaves SERPINB4 in its
RCL, at least after the amino acid Leu354 at the P1-position in the
sequence 351VVELQSSPS358 (Fig. 2C).
Stoichiometry of inhibition of GrM and SERPINB4
The interaction of a serpin with its physiological target protease
usually results in complex formation with a stoichiometry of
inhibition (SI) value close to 1. The SI value indicates how many
serpin-molecules are needed to inhibited one molecule of target
protease. If a serpin is also a substrate in parallel to an inhibitor of
its target protease, this is reflected by a SI value greater than 1.
The SI value for inhibition of GrM by SERPINB4 was determined
by measurement of residual GrM activity at increasing [SER-
PINB4]0/[GrM]0 ratios (Fig. 3A). Complete inhibition of GrM
activity was obtained at a [SERPINB4]0/[GrM]0 ratio of
1.660.07 (mean 6 SD of 4 independent experiments) (Fig. 3A).
This indicates that about three molecules of SERPINB4 are
needed to inhibit two GrM molecules.
Kinetic analysis of the inhibition of GrM activity by
SERPINB4
To determine the rate of complex formation between GrM and
SERPINB4, the apparent second order rate constant (kinh) was
measured under second order conditions. Upon incubation of
Figure 2. Mutation of the SERPINB4 RCL at the P2-P1-P19
positions completely abolishes complex formation with human
GrM. (A) A RCL-mutant of SERPINB4 was employed in which the amino
acids at the putative P2(Glu353)-P1(Leu354)-P19(Ser355) positions were
mutated into P2(Gln353)-P1(Gly354)-P19(Ala355). Purified recombinant
GrM (0.9 mM), GrM-SA (0.9 mM), SERPINB4 (0.9 mM), and SERPINB4
RCL-mutant (0.9 mM) were incubated for 1 h at 37uC. All samples were
treated with PNGase F, separated by SDS-PAGE, and immunoblotted for
GrM. Bound antibodies were visualized using DAB. (B) Cell lysates of
293T cells transfected with C-terminal GFP-conjugated SERPINB4 or an
empty vector (mock) were incubated with recombinant GrM (0.5 mM)
for 1 h at 37uC. Subsequently, samples were immunoblotted for GFP.
SERPINB4-GFP represents the full length protein, whereas SERPINB4*-
GFP depicts the C-terminal cleavage product. (C) Schematic represen-
tation of C-terminal GFP-conjugated SERPINB4, including the GrM
cleavage site after Leu354 at the P1-position in the RCL.
doi:10.1371/journal.pone.0022645.g002
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recombinant GrM with equimolar concentrations of SERPINB4
samples were taken in time to measure the residual GrM-activity.
Addition of a synthetic chromogenic leucine substrate to these
aliquots revealed that the concentration of active GrM decreased
linear in time (Fig. 3B). The apparent second order rate constant (kinh)
was calculated from the slope of the plot of reciprocal residual active
GrM over time and was determined to be 1.3 (60.05)6104 M21s21
(mean6 SD of 3 independent experiments). This kinh was not affected
by inclusion of the glycosaminoglycan heparin in these experiments,
which is a known co-factor of several serpins that enhances the kinh
towards their target proteases [33] (data not shown).
SERPINB4 inhibits cleavage of natural macromolecular
substrates by GrM
The inhibitory effect of SERPINB4 on the activity of human
GrM was further investigated using natural macromolecular
substrates of GrM. GrM and SERPINB4 were incubated at
various concentration-ratios and GrM-activity towards two known
direct GrM-substrates [10,11] in a Jurkat tumor cell lysate was
determined by immunoblotting (Fig. 4). As expected, in the
absence of SERPINB4, human recombinant GrM efficiently
cleaved the 55 kDa a-tubulin subunit as well as the 37 kDa
nucleolar phosphoprotein nucleophosmin. Recombinant SER-
PINB4 impaired cleavage of both a-tubulin and nucleophosmin by
GrM in a concentration-dependent manner (Fig. 4). Excessive
concentrations of SERPINB4 over GrM completely inhibited
GrM activity towards a-tubulin, whereas some nucleophosmin
cleavage was still observed, suggesting that nucleophosmin is a
more efficient GrM-substrate than a-tubulin. b-actin served as a
loading control (Fig. 4). In conclusion, SERPINB4 inhibits GrM-
mediated cleavage of the natural macromolecular substrates a-
tubulin and nucleophosmin in a tumor cell lysate.
Overexpression of SERPINB4 inhibits recombinant
GrM-induced as well as NK cell-mediated cell death
To examine whether SERPINB4 also inhibits the proteolytic
activity of GrM in tumor cells, the effect of overexpression of
SERPINB4 in HeLa cells on GrM-induced cell death was
investigated. First, SERPINB4 RNA and protein expression by
HeLa cells stable transfected with SERPINB4, SERPINB4 RCL-
mutant, or an empty vector were determined. RT-PCR analysis
revealed SERPINB4 RNA expression in both HeLa cells that
overexpressed SERPINB4 and SERPINB4 RCL-mutant (Fig. 5A,
upper panel). Mock-transfected HeLa cells and HeLa cells
transfected with the empty vector did not express SERPINB4
RNA. GAPDH RNA expression served as a control for RNA/
cDNA input (Fig. 5A, lower panel). In accordance with the RNA
expression, immunoblot analysis revealed SERPINB4 protein
expression by both HeLa cells stable transfected with SERPINB4
and SERPINB4 RCL-mutant, and not by mock-transfected HeLa
cells or HeLa cells transfected with the empty vector (Fig. 5B).
Second, a GrM cell death assay was employed in which the pore-
forming protein SLO was used to deliver recombinant GrM into
HeLa cells that overexpressed either SERPINB4 or SERPINB4
RCL-mutant. As a control, we included the catalytically inactive
GrM mutant (i.e. GrM-SA). The methylene blue assay revealed
that treatment of the cells with only a sublytic dose of SLO
resulted in about 20% reduction of viable cells. As expected, the
percentage of viable HeLa cells that overexpressed inactive
SERPINB4 RCL-mutant significantly decreased upon treatment
with SLO and recombinant GrM, but not with recombinant GrM
only, SLO only, or the SLO/GrM-SA combination (Fig. 5C, left
panel). In contrast, GrM-induced cell death of HeLa cells was fully
rescued by overexpression of SERPINB4 (Fig. 5C, right panel).
Similar results were obtained on a single cell level by staining with
Annexin V and PI and subsequently FACS analysis. Again, GrM-
induced cell death was inhibited by overexpression of SERPINB4
(Fig. 5D).
To further determine whether GrM is inactivated by SER-
PINB4 after intercellular delivery, cleavage of the preferred GrM-
Figure 3. Kinetic analyses of GrM-inhibition by SERPINB4. (A)
Purified recombinant human GrM (2 mM) was incubated with different
concentrations of recombinant SERPINB4 (0–3 mM) for 2 h at 37uC.
Residual GrM activity was monitored by addition of a synthetic
chromogenic leucine substrate (1 mM) and measuring A405 in time.
The fractional activity (velocity of substrate hydrolysis by GrM in the
presence of SERPINB4/velocity of substrate hydrolysis by GrM without
SERPINB4) was plotted against the ratio of [SERPINB4]0/[GrM]0. Linear
regression analysis was used to calculate the x-intercept as a value for
the SI and determined to be 1.660.07 (mean 6 SD of 4 independent
experiments). (B) The apparent second order rate constant (kinh) of the
inhibition of GrM by SERPINB4 was determined under second order
conditions. Equimolar concentrations of recombinant human GrM and
SERPINB4 were incubated. Aliquots were removed at different time
points and the reaction was directly stopped by 20-fold dilution with
buffer containing a synthetic chromogenic leucine substrate (1 mM).
Residual GrM activity was determined by measuring the velocity of
substrate hydrolysis in time at A405. These velocities were converted to
residual active GrM concentrations using a GrM concentration standard
curve. The apparent second order rate constant (kinh) was calculated
from the slope of the plot of reciprocal residual active GrM over time
and determined to be 1.36104 M21s21 (graph indicates one represen-
tative example of three independent experiments with similar results).
doi:10.1371/journal.pone.0022645.g003
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substrate nucleophosmin was investigated. As expected, nucleo-
phosmin was cleaved upon SLO-mediated delivery of GrM, and
not GrM-SA, into HeLa cells overexpressing SERPINB4 RCL
mutant (Fig. 5D, right lanes). In contrast, GrM-mediated
intracellular cleavage of nucleophosmin was inhibited by overex-
pression of SERPINB4 (Fig. 5D, left lanes), indicating that GrM is
inactivated by SERPINB4 upon intracellular delivery.
In addition to exogenous recombinant GrM-induced cell death,
we also investigated whether SERPINB4 inhibits endogenous
native GrM-induced cell death. The NK cell line KHYG-1, which
is known to express large amounts of GrM and hardly, if any, GrA
and GrB [34], was co-cultured in various ratios with HeLa cells
stably transfected with either SERPINB4 or SERPINB4 RCL
mutant. HeLa cells were killed by KHYG-1 cells in a ratio
dependent manner (Fig. 6). In contrast, overexpression of
SERPINB4 significantly inhibited KHYG-1 mediated cell death
as compared to HeLa cells stably transfected with SERPINB4
RCL mutant. These results indicate that cellular overexpression of
SERPINB4 inhibits recombinant GrM-induced as well as NK cell-
mediated cell death and that this inhibition is dependent on the
RCL of the serpin.
Discussion
The granule-exocytosis pathway is the major mechanism for
cytotoxic lymphocytes to kill tumor and virus-infected cells
[1,2,3,4]. Tumor cells can evade GrB-mediated cell death by
expression of the intracellular serine protease inhibitor SERPINB9
[17,18]. However, such physiological intracellular inhibitors are
unknown for the other four human granzymes. In mice, GrM is
inhibited by the murine serpin SPI-CI, which protects cells from
GrM-mediated cell death [35]. SPI-CI is unique for mice and no
human orthologue is known. In the present study, we show for the
first time that human GrM also has an endogenous intracellular
inhibitor that protects cells from GrM-mediated killing. We have
demonstrated that GrM cleaves SERPINB4 in its RCL after P1-
Leu, resulting in the formation of a typical serpin-protease SDS-
stable complex (Figs. 1, 2, 3). Furthermore, SERPINB4 inhibited
the proteolytic activity of GrM towards natural macromolecular
substrates (Fig. 4 and 5E) and overexpression of SERPINB4 in
HeLa cells inhibited recombinant GrM-induced as well as NK-cell
mediated cell death (Fig. 5 and 6).
Our findings are consistent with the facts that GrM preferably
cleaves after a P1-Leu and, to a lesser extent, after P1-Met [30,36],
and that SERPINB4 harbours a Leu at the P1-position in its RCL
[31,37]. Indeed, mutation of the P2-P1-P19 triplet in the
SERPINB4 RCL completely abolished complex formation with
GrM (Fig. 2A) and N-terminal sequencing revealed that GrM
cleaved SERPINB4 at least after the Leu residue at the RCL P1-
position (Fig. 2C). In addition, protection of HeLa cells against
both recombinant GrM-induced and NK cell-mediated cell death
by cellular overexpression of SERPINB4 also depended on the
RCL of the serpin (Fig. 5 and 6). Although SERPINB4 is the only
intracellular serpin that meets the primary specificity of human
GrM in that it harbours a Leu or Met amino acid at the putative
P1-position in its RCL [32,38], we cannot fully exclude that other
intracellular serpins than SERPINB4 inhibit human GrM. Few
serpins are known to use more than one RCL P1-residue to inhibit
different target proteases, thereby broadening their inhibitory
profile [38]. Interestingly, the GrB-inhibitor SERPINB9 harbours
a Met residue at the putative P39 position in its RCL. Indeed,
GrM cleaves SERPINB9, however, an SI value of 59 points to a
substrate rather than an inhibitor [30]. Therefore, it has been
proposed that cleavage and inactivation of SERPINB9 by GrM
clears the way for GrB-induced target cell killing [30]. Whether
intracellular serpins other than SERPINB4 exist that inhibit
human GrM activity remains an open question.
Whether SERPINB4 is a physiologic inhibitor of GrM remains
to be investigated. We showed that SERPINB4 forms a typical
serpin-protease SDS-stable complex with both recombinant and
native human GrM (Fig. 1). Kinetic analysis of GrM-inhibition by
SERPINB4 revealed a SI of 1.6 (Fig. 3A), indicating that about
two-third of the SERPINB4 molecules forms a covalent complex
with GrM and inhibits its activity, whereas about one-third of the
SERPINB4 molecules is a substrate of GrM without trapping the
protease. This corresponds with the relative intensity of the bands
in Fig. 1A representing complexed and cleaved SERPINB4. The
SI for SERPINB4 and GrM is in the similar range as the
Figure 4. SERPINB4 inhibits GrM-mediated cleavage of macromolecular substrates. Indicated concentrations of recombinant GrM and
SERPINB4 were incubated for 2 h at 37uC. Jurkat tumor cell lysate (2 mg) was added to the samples and incubated for another 4 h at 37uC to
determine the residual GrM-activity towards macromolecular substrates. Finally, all samples were immunoblotted for a-tubulin, nucleophosmin, and
b-actin.
doi:10.1371/journal.pone.0022645.g004
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physiological interaction between SERPINB9 and caspase-1
(SI,1.7) [39] and somewhat higher as compared to SERPINB9
and GrB (SI,1.0) [40]. The inhibitory potency of SERPINB4
towards GrM seems different for a small molecular substrate
(SI = 1.6; Fig. 3A) as compared to macromolecular substrates
(SI.1.6; Fig. 4). The reason for this discrepancy remains unclear,
but might be due to our recombinant proteins. It could be that a
tiny fraction (,1%) of our recombinant GrM is not properly
inhibited by SERPINB4 due to abnormal folding or glycosylation
by P. pastoris, but retains its proteolytic activity. If so, this will not
influence the determined SI-value significantly (Fig. 3A). However,
cleavage of nucleophosmin by GrM is very efficient and occurs
already at nanomolar concentrations of GrM [11], therefore a tiny
fraction of non-inhibited GrM can be demonstrated by Western
blot analysis (Fig. 4). The determined kinh of 1.3610
4 M21s21 for
the rate of GrM inhibition by SERPINB4 (Fig. 3B) was into a
similar range as compared with other SERPINB4-protease
interactions. Previously, SERPINB4 has been demonstrated to
inhibit cathepsin G and chymase with kinh-values of
Figure 5. Overexpression of SERPINB4 in HeLa cells inhibits
GrM-induced cell death. (A) RT-PCR analysis of stably transfected
HeLa cells for SERPINB4 and GAPDH mRNA expression (upper and lower
panel, respectively). (B) Immunoblot analysis of SERPINB4 protein
expression by HeLa cells stably transfected with pcDNA3 SERPINB4,
pcDNA3 SERPINB4 RCL-mutant or pcDNA3 empty vector. (C) HeLa cells
stably transfected with SERPINB4 or SERPINB4 RCL-mutant were treated
with the indicated combinations of a sublytic dose of SLO (500 ng/ml),
recombinant GrM (0.5 mM), and/or recombinant GrM-SA (0.5 mM) for
16 h at 37uC. Viable cells were quantified using the methylene blue
assay. Data represent the percentages of viable cells as compared to
HeLa cells that overexpressed SERPINB4 RCL-mutant and were treated
with buffer only, which was set as 100%. Figure represents the mean 6
Figure 6. Overexpression of SERPINB4 in HeLa cells inhibits NK
cell-mediated cell death. HeLa cells stably transfected with SERPINB4
or SERPINB4 RCL-mutant were loaded with the fluorescent cell staining
dye CFDA-SE and co-cultured with KHYG-1 NK cells in varying E:T ratio’s
for 16 h at 37uC. Cells were stained with PI and analyzed by flow
cytometry. HeLa cells were separated from KHYG-1 cells by gating for
CFDA-SE positive cells. Depicted is the percentage of specific
cytotoxicity (mean 6 SD, n=3, * p,0.05, ** p,0.005).
doi:10.1371/journal.pone.0022645.g006
SD of 4 independent experiments; * p,0.05. (D) HeLa cells stably
transfected with SERPINB4 or SERPINB4 RCL-mutant were treated with
the indicated combinations of a sublytic dose of SLO (500 ng/ml),
recombinant GrM (1 mM), and/or recombinant GrM-SA (1 mM) for 20 h
at 37uC. Cell viability was determined using flow cytometry, with
AnnexinV and PI negative cells considered viable (mean 6 S.D., n= 3,
** p,0.005). (E) HeLa cells stably transfected with SERPINB4 or
SERPINB4 RCL-mutant were treated with the indicated combinations
of a sublytic dose of SLO (500 ng/ml), recombinant GrM (1 mM), and/or
recombinant GrM-SA (1 mM) for 4 h at 37uC. Total cell lysates were
immunoblotted using antibodies against nucleophosmin and nm23H-1
(which served as a loading control).
doi:10.1371/journal.pone.0022645.g005
SERPINB4 Inhibits Human Granzyme M
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22645
1.06105 M21s21 and 2.86104 M21s21, respectively [41]. The
kinh-value for SERPINB4 and GrM is lower as compared to
SERPINB9 and GrB (1.76106 M21s21) [40]. However, a
physiological inhibitory role has been proposed for serpins with
a relative low kinh-value [32], for instance inhibition of TNF-
mediated apoptosis by SERPINB4 via cathepsin G (kinh
1.06105 M21s21) [26], endogenous anti-inflammatory action of
SERPINB9 via inhibition of caspase 1 (kinh 7610
2 M21s21) [39],
activated protein C inhibition by Protein C inhibitor (SERPINA5)
(kinh 2.5610
4 M21s21) during anti-coagulation [42], and comple-
ment C1 and kallikrein inhibition by C1-inhibitor (SERPING1)
(kinh 2.8610
321.76104 M21s21) [43]. In this context, it should
also be mentioned that, like for other serpins [44], the inhibitory
capacity of SERPINB4 towards GrM or other serine proteases
could potentially be further enhanced by serpin cofactors,
although here we excluded a role for heparin (data not shown).
We provide in vitro evidence that overexpression of SERPINB4
inhibits both GrM-induced and NK cell-mediated cell death in
tumor cells (Fig. 5 and 6). Whether SERPINB4 indeed is a
physiological GrM-inhibitor in humans is ultimately determined
by local concentrations of GrM and SERPINB4 in vivo.
In normal tissue, SERPINB4 is mainly expressed by stratified
squamous epithelium of both the upper gastrointestinal tract and
the female genitourinary system, and by pseudo-stratified
columnar epithelium of the conducting airways [45]. Interestingly,
tumors originating from these epithelial tissues also express
SERPINB4, i.e. squamous cell carcinomas of the cervix [46],
head and neck, and lung [45]. Moreover, elevated SERPINB4
levels in patients with squamous cell carcinomas are associated
with an advanced stage of tumor progression and poor disease-free
survival [47,48]. This indicates that expression of SERPINB4 is
beneficial for tumor cells. Indeed, SERPINB4 inhibits both
radiation- and TNF-induced apoptosis in transfected cell lines,
probably by inhibition of the p38 MAPK pathway and the
proteolytic activity of endogenous cathepsin G, respectively
[26,49]. Our current findings that SERPINB4 binds to human
GrM and that cellular overexpression of SERPINB4 inhibits
GrM-induced cell death suggest a novel function for SERPINB4,
i.e. enhancement of tumor progression through interference with
the granule-exocytosis cell death pathway of cytotoxic lympho-
cytes. This intriguing concept has been well studied for
SERPINB9-expressing tumor cells that efficiently inhibit GrB-
induced cell death [17]. SERPINB9 expression in several types of
tumors is associated with a poor clinical outcome of patients
[19,20]. In analogy with SERPINB9, SERPINB4 expression may
constitute a novel mechanism by which human squamous cell
carcinoma tumor cells evade GrM-mediated cytotoxic lympho-
cyte-induced cell death.
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